Retatrutide is an investigational peptide that acts as a triple receptor agonist, engaging the GLP-1, GIP and glucagon receptors simultaneously. It is currently the subject of clinical trials and is not an approved medicine.
Most single-mechanism metabolic peptides act on one receptor. Retatrutide's research interest stems from the combined activity across three pathways, which preclinical and trial research has examined in the context of appetite signalling, glucose handling and energy expenditure.
Because retatrutide is unlicensed and investigational, it sits firmly in the research-compound category. It should not be confused with approved, prescription-only products, and the research literature remains the appropriate reference point.
Onyx Peptides supplies retatrutide as a lyophilised powder across several vial strengths, each HPLC-verified to at least 99% purity with a batch certificate available on request.
This article is provided for educational and research-reference purposes only. It is not medical advice. All products are supplied strictly for in-vitro laboratory research use, not for human or veterinary consumption.